EMA Recommends Extending Indications for Lisocabtagene Maraleucel By Ogkologos - November 12, 2025 67 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns the treatment of adult patients with relapsed or refractory mantle cell lymphoma Source RELATED ARTICLESMORE FROM AUTHOR The Legacy of the ESMO Patient Engagement Summit 2025: Advancing Rights of Patients with Cancer via Cross-Border Best Practices and Collaboration Sustained PFS Benefit of Imlunestrant Over SoC in Patients with ESR1-mutated Advanced Breast Cancer ESMO Welcomes Launch of Health Package Introducing EU Measures That Can Boost Innovation in Oncology and Help Prevent New Cancer Cases MOST POPULAR Favourable Response More Likely with Neoadjuvant Dual Immune Checkpoint Inhibitor Than... April 11, 2024 Young Mom-of-Three Learns She Has Stage 4 Breast Cancer, 5 Days... January 4, 2021 A New Era of Early Cancer Detection With Blood Test May... September 11, 2022 ESMO Publishes First-Ever Guidance on Validation Requirements for AI-Based Biomarkers in... November 18, 2025 Load more HOT NEWS 2021 ASCO Annual Meeting: New Treatments and Research Advances in Esophageal... FDA Approves Neoadjuvant and Adjuvant Pembrolizumab for Resectable Locally Advanced Head... Coronavirus and cancer – July updates Green Beret With Lung Cancer Surprised With Hundreds Of ‘Thank You’...
